Chiara Zecca1,2, Giulio Disanto3, Rosaria Sacco3, Sharon MacLachlan4, Jens Kuhle5, Sreeram V Ramagopalan6, Claudio Gobbi3,7. 1. Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano Civico e Italiano, Via Tesserete 46, 6903, Lugano, Switzerland. chiara.zecca@eoc.ch. 2. Faculty of Biomedical Sciences, Università della Svizzera Italiana, Via Buffi 13, 6900, Lugano, Switzerland. chiara.zecca@eoc.ch. 3. Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano Civico e Italiano, Via Tesserete 46, 6903, Lugano, Switzerland. 4. Evidera, The Ark, 201 Talgarth Rd, London, W6 8BJ, UK. 5. Departments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland. 6. Bristol-Myers Squibb, Sanderson Rd, Denham, Uxbridge, UB8 1DH, UK. 7. Faculty of Biomedical Sciences, Università della Svizzera Italiana, Via Buffi 13, 6900, Lugano, Switzerland.
Abstract
BACKGROUND: Data on cancer prevalence and incidence in multiple sclerosis (MS) patients are controversial. This study is aimed at estimating cancer risk in MS patients. METHODS: Nested case-control study using data collected between 01/01/1987 and 28/02/2016 from the United Kingdom Clinical Practice Research Datalink. Cancer diagnoses after first MS code (index date) was counted in 10,204 MS patients and 39,448 controls matched by sex, age, general practitioner, and registration year. Cancer rates were compared using multivariable Cox regression models. Ethics approval was not required. RESULTS: Cancer was reported in 433 (4.41%) MS patients and 2014 (5.31%) controls after index date. Cancer risk was associated with gender (HR for female = 0.88, 95% CI = 0.81-0.96, p = 0.004), age at index date (HR = 1.06, 95% CI = 1.06-1.07, p < 0.001), and index year (HR = 1.01, 95% CI = 1.00-1.02, p = 0.016), but not with MS status (HR = 0.95, 95% CI = 0.86-1.05, p = 0.323). A significant interaction between MS status and index year was found (HR = 1.02, 95% CI = 1.00-1.04, p = 0.022). Cancer risk was positively associated with index year among MS patients (HR = 1.03, 95% CI = 1.01-1.05; p = 0.010), but not controls (HR = 1.01, 95% CI = 0.99-1.02; p = 0.144). MS patients compared to controls had no increased risk for any specific cancer type. CONCLUSIONS: Overall cancer risk was similar in multiple sclerosis patients and matched controls. The frequency of cancer diagnoses has increased over time among MS patients but not in controls.
BACKGROUND: Data on cancer prevalence and incidence in multiple sclerosis (MS) patients are controversial. This study is aimed at estimating cancer risk in MS patients. METHODS: Nested case-control study using data collected between 01/01/1987 and 28/02/2016 from the United Kingdom Clinical Practice Research Datalink. Cancer diagnoses after first MS code (index date) was counted in 10,204 MS patients and 39,448 controls matched by sex, age, general practitioner, and registration year. Cancer rates were compared using multivariable Cox regression models. Ethics approval was not required. RESULTS:Cancer was reported in 433 (4.41%) MS patients and 2014 (5.31%) controls after index date. Cancer risk was associated with gender (HR for female = 0.88, 95% CI = 0.81-0.96, p = 0.004), age at index date (HR = 1.06, 95% CI = 1.06-1.07, p < 0.001), and index year (HR = 1.01, 95% CI = 1.00-1.02, p = 0.016), but not with MS status (HR = 0.95, 95% CI = 0.86-1.05, p = 0.323). A significant interaction between MS status and index year was found (HR = 1.02, 95% CI = 1.00-1.04, p = 0.022). Cancer risk was positively associated with index year among MS patients (HR = 1.03, 95% CI = 1.01-1.05; p = 0.010), but not controls (HR = 1.01, 95% CI = 0.99-1.02; p = 0.144). MS patients compared to controls had no increased risk for any specific cancer type. CONCLUSIONS: Overall cancer risk was similar in multiple sclerosispatients and matched controls. The frequency of cancer diagnoses has increased over time among MS patients but not in controls.
Authors: Nete Munk Nielsen; Klaus Rostgaard; Søren Rasmussen; Nils Koch-Henriksen; Hans H Storm; Mads Melbye; Henrik Hjalgrim Journal: Int J Cancer Date: 2006-02-15 Impact factor: 7.396
Authors: Dimitrios Papadopoulos; Panagiotis Gklinos; Giorgos Psarros; Konstantina Drellia; Eumorphia Maria Delicha; Tim Friede; Dimos D Mitsikostas; Richard S Nicholas Journal: J Neurol Date: 2022-01-23 Impact factor: 4.849